SCPS — Scopus Biopharma Share Price
Last trade - 00:00- $0.00m
- -$1.41m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.
Directors
- Joshua Lamstein CHM (51)
- Ashish Sanghrajka PRE (47)
- Robert Gibson VCH (41)
- Aharon Schwartz CEX (79)
- Ira Greenspan DRC (62)
- Mordechai Hacham DRC (49)
- Joshua Levine DRC (63)
- David Battleman IND (54)
- David Buckel IND (59)
- Raphael Hofstein IND (71)
- Paul Hopper IND (64)
- David Weild IND (64)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- April 18th, 2017
- Public Since
- December 16th, 2020
- No. of Shareholders
- 174
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 42,084,264
- Address
- 420 Lexington Ave Rm 300, NEW YORK, 10170-0399
- Web
- https://scopusbiopharma.com/
- Phone
- +1 2124792513
- Auditors
- WOLF & COMPANY, P.C.
Upcoming Events for SCPS
Similar to SCPS
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 23:08 UTC, shares in Scopus Biopharma are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Scopus Biopharma last closed at $0.00 and the price had moved by -99.8% over the past 365 days. In terms of relative price strength the Scopus Biopharma share price has underperformed the S&P500 Index by -99.83% over the past year.
The overall consensus recommendation for Scopus Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Scopus Biopharma does not currently pay a dividend.
Scopus Biopharma does not currently pay a dividend.
Scopus Biopharma does not currently pay a dividend.
To buy shares in Scopus Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Scopus Biopharma had a market capitalisation of $0.00m.
Here are the trading details for Scopus Biopharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SCPS
Based on an overall assessment of its quality, value and momentum Scopus Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Scopus Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -99.78%.
As of the last closing price of $0.00, shares in Scopus Biopharma were trading -99.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Scopus Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Scopus Biopharma's management team is headed by:
- Joshua Lamstein - CHM
- Ashish Sanghrajka - PRE
- Robert Gibson - VCH
- Aharon Schwartz - CEX
- Ira Greenspan - DRC
- Mordechai Hacham - DRC
- Joshua Levine - DRC
- David Battleman - IND
- David Buckel - IND
- Raphael Hofstein - IND
- Paul Hopper - IND
- David Weild - IND